159 related articles for article (PubMed ID: 32966782)
1. SFPQ Depletion Is Synthetically Lethal with BRAF
Klotz-Noack K; Klinger B; Rivera M; Bublitz N; Uhlitz F; Riemer P; Lüthen M; Sell T; Kasack K; Gastl B; Ispasanie SSS; Simon T; Janssen N; Schwab M; Zuber J; Horst D; Blüthgen N; Schäfer R; Morkel M; Sers C
Cell Rep; 2020 Sep; 32(12):108184. PubMed ID: 32966782
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
3. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
4. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
5. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
6. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
7.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
9. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
[TBL] [Abstract][Full Text] [Related]
14. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
16. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
Minoo P; Moyer MP; Jass JR
J Pathol; 2007 Jun; 212(2):124-33. PubMed ID: 17427169
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
18. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
19. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
20. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]